1
|
Egners A, Cramer T, Wallach I, Berndt N. Kinetic Modeling of Hepatic Metabolism and Simulation of Treatment Effects. Methods Mol Biol 2024; 2769:211-225. [PMID: 38315400 DOI: 10.1007/978-1-0716-3694-7_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
Abstract
Mathematical modeling is a promising strategy to fill the experimentally unapproachable knowledge gaps about the relative contribution of various molecular processes to cellular metabolic function. To this end, we developed detailed kinetic models of the central metabolism of different cell types, comprising multiple metabolic functionalities. We used the model to simulate metabolic changes in several cell types under different experimental settings in health and disease. In this way, we show that it is possible to decipher and characterize the relative influence of various metabolic pathways and enzymes to overall metabolic performance and phenotype.Quantitative Systems Metabolism (QSM™) allows quantitative assessment of metabolic functionality and metabolic profiling based on proteomic data. Here, we describe the technique, namely, molecular resolved kinetic modeling, underlying QSM™. We explain the necessary steps for the generation of cell-specific models to functionally interpret proteomic data and point out some unresolved challenges and open questions.
Collapse
Affiliation(s)
- Antje Egners
- Molecular Tumor Biology, Department of General, Visceral and Transplantation Surgery, RWTH University Hospital, Aachen, Germany
| | - Thorsten Cramer
- Molecular Tumor Biology, Department of General, Visceral and Transplantation Surgery, RWTH University Hospital, Aachen, Germany
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
- NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Iwona Wallach
- Deutsches Herzzentrum der Charité (DHZC), Institute of Computer-assisted Cardiovascular Medicine, Berlin, Germany
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Nikolaus Berndt
- Deutsches Herzzentrum der Charité (DHZC), Institute of Computer-assisted Cardiovascular Medicine, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.
| |
Collapse
|
2
|
Villalba A, Fonolleda M, Murillo M, Rodriguez-Fernandez S, Ampudia RM, Perna-Barrull D, Raina MB, Quirant-Sanchez B, Planas R, Teniente-Serra A, Bel J, Vives-Pi M. Partial remission and early stages of pediatric type 1 diabetes display immunoregulatory changes. A pilot study. Transl Res 2019; 210:8-25. [PMID: 30953609 DOI: 10.1016/j.trsl.2019.03.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 03/04/2019] [Accepted: 03/07/2019] [Indexed: 02/06/2023]
Abstract
Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.
Collapse
Affiliation(s)
- Adrian Villalba
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - Mireia Fonolleda
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - Marta Murillo
- Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain
| | | | - Rosa-Maria Ampudia
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - David Perna-Barrull
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - Maria Belen Raina
- Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain
| | | | - Raquel Planas
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - Aina Teniente-Serra
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain
| | - Joan Bel
- Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain
| | - Marta Vives-Pi
- Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain; CIBER of Diabetes and Associated Metabolic Disease (CIBERDEM). ISCIII, Barcelona, Spain.
| |
Collapse
|
3
|
Xie F, Chan JCN, Ma RCW. Precision medicine in diabetes prevention, classification and management. J Diabetes Investig 2018; 9:998-1015. [PMID: 29499103 PMCID: PMC6123056 DOI: 10.1111/jdi.12830] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 02/12/2018] [Indexed: 12/18/2022] Open
Abstract
Diabetes has become a major burden of healthcare expenditure. Diabetes management following a uniform treatment algorithm is often associated with progressive treatment failure and development of diabetic complications. Recent advances in our understanding of the genomic architecture of diabetes and its complications have provided the framework for development of precision medicine to personalize diabetes prevention and management. In the present review, we summarized recent advances in the understanding of the genetic basis of diabetes and its complications. From a clinician's perspective, we attempted to provide a balanced perspective on the utility of genomic medicine in the field of diabetes. Using genetic information to guide management of monogenic forms of diabetes represents the best-known examples of genomic medicine for diabetes. Although major strides have been made in genetic research for diabetes, its complications and pharmacogenetics, ongoing efforts are required to translate these findings into practice by incorporating genetic information into a risk prediction model for prioritization of treatment strategies, as well as using multi-omic analyses to discover novel drug targets with companion diagnostics. Further research is also required to ensure the appropriate use of this information to empower individuals and healthcare professionals to make personalized decisions for achieving the optimal outcome.
Collapse
Affiliation(s)
- Fangying Xie
- Department of Medicine and TherapeuticsPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
| | - Juliana CN Chan
- Department of Medicine and TherapeuticsPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- Hong Kong Institute of Diabetes and ObesityPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- Li Ka Shing Institute of Health SciencesPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- CUHK‐SJTU Joint Research Centre in Diabetes Genomics and Precision MedicinePrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
| | - Ronald CW Ma
- Department of Medicine and TherapeuticsPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- Hong Kong Institute of Diabetes and ObesityPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- Li Ka Shing Institute of Health SciencesPrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
- CUHK‐SJTU Joint Research Centre in Diabetes Genomics and Precision MedicinePrince of Wales HospitalThe Chinese University of Hong KongShatinHong Kong
| |
Collapse
|
4
|
DNA-Methylation and Body Composition in Preschool Children: Epigenome-Wide-Analysis in the European Childhood Obesity Project (CHOP)-Study. Sci Rep 2017; 7:14349. [PMID: 29084944 PMCID: PMC5662763 DOI: 10.1038/s41598-017-13099-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 09/19/2017] [Indexed: 01/16/2023] Open
Abstract
Adiposity and obesity result from the interaction of genetic variation and environmental factors from very early in life, possibly mediated by epigenetic processes. Few Epigenome-Wide-Association-Studies have identified DNA-methylation (DNAm) signatures associated with BMI and body composition in children. Body composition by Bio-Impedance-Analysis and genome-wide DNAm in whole blood were assessed in 374 pre-school children from four European countries. Associations were tested by linear regression adjusted for sex, age, centre, education, 6 WBC-proportions according to Houseman and 30 principal components derived from control probes. Specific DNAm variants were identified to be associated with BMI (212), fat-mass (230), fat-free-mass (120), fat-mass-index (24) and fat-free-mass-index (15). Probes in genes SNED1(IRE-BP1), KLHL6, WDR51A(POC1A), CYTH4-ELFN2, CFLAR, PRDM14, SOS1, ZNF643(ZFP69B), ST6GAL1, C3orf70, CILP2, MLLT4 and ncRNA LOC101929268 remained significantly associated after Bonferroni-correction of P-values. We provide novel evidence linking DNAm with (i) altered lipid and glucose metabolism, (ii) diabetes and (iii) body size and composition in children. Both common and specific epigenetic signatures among measures were also revealed. The causal direction with phenotypic measures and stability of DNAm variants throughout the life course remains unclear and longitudinal analysis in other populations is required. These findings give support for potential epigenetic programming of body composition and obesity.
Collapse
|
5
|
Roberts FR, Hupple C, Norowski E, Walsh NC, Przewozniak N, Aryee KE, Van Dessel FM, Jurczyk A, Harlan DM, Greiner DL, Bortell R, Yang C. Possible type 1 diabetes risk prediction: Using ultrasound imaging to assess pancreas inflammation in the inducible autoimmune diabetes BBDR model. PLoS One 2017; 12:e0178641. [PMID: 28605395 PMCID: PMC5468055 DOI: 10.1371/journal.pone.0178641] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 05/16/2017] [Indexed: 11/26/2022] Open
Abstract
Background/Aims Studies of human cadaveric pancreas specimens indicate that pancreas inflammation plays an important role in type 1 diabetes pathogenesis. Due to the inaccessibility of pancreas in living patients, imaging technology to visualize pancreas inflammation is much in need. In this study, we investigated the feasibility of utilizing ultrasound imaging to assess pancreas inflammation longitudinally in living rats during the progression leading to type 1 diabetes onset. Methods The virus-inducible BBDR type 1 diabetes rat model was used to systematically investigate pancreas changes that occur prior to and during development of autoimmunity. The nearly 100% diabetes incidence upon virus induction and the highly consistent time course of this rat model make longitudinal imaging examination possible. A combination of histology, immunoblotting, flow cytometry, and ultrasound imaging technology was used to identify stage-specific pancreas changes. Results Our histology data indicated that exocrine pancreas tissue of the diabetes-induced rats underwent dramatic changes, including blood vessel dilation and increased CD8+ cell infiltration, at a very early stage of disease initiation. Ultrasound imaging data revealed significant acute and persistent pancreas inflammation in the diabetes-induced rats. The pancreas micro-vasculature was significantly dilated one day after diabetes induction, and large blood vessel (superior mesenteric artery in this study) dilation and inflammation occurred several days later, but still prior to any observable autoimmune cell infiltration of the pancreatic islets. Conclusions Our data demonstrate that ultrasound imaging technology can detect pancreas inflammation in living rats during the development of type 1 diabetes. Due to ultrasound’s established use as a non-invasive diagnostic tool, it may prove useful in a clinical setting for type 1 diabetes risk prediction prior to autoimmunity and to assess the effectiveness of potential therapeutics.
Collapse
Affiliation(s)
| | | | - Elaine Norowski
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Nicole C. Walsh
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Natalia Przewozniak
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Ken-Edwin Aryee
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Filia M. Van Dessel
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Agata Jurczyk
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - David M. Harlan
- Department of Medicine, University of Massachusetts Medical School, Massachusetts, United States of America
| | - Dale L. Greiner
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Rita Bortell
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Chaoxing Yang
- Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
6
|
Liston A, Todd JA, Lagou V. Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes. Trends Mol Med 2017; 23:181-194. [DOI: 10.1016/j.molmed.2016.12.005] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 12/07/2016] [Accepted: 12/11/2016] [Indexed: 12/13/2022]
|
7
|
Dooley J, Tian L, Schonefeldt S, Delghingaro-Augusto V, Garcia-Perez JE, Pasciuto E, Di Marino D, Carr EJ, Oskolkov N, Lyssenko V, Franckaert D, Lagou V, Overbergh L, Vandenbussche J, Allemeersch J, Chabot-Roy G, Dahlstrom JE, Laybutt DR, Petrovsky N, Socha L, Gevaert K, Jetten AM, Lambrechts D, Linterman MA, Goodnow CC, Nolan CJ, Lesage S, Schlenner SM, Liston A. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat Genet 2016; 48:519-27. [PMID: 26998692 DOI: 10.1038/ng.3531] [Citation(s) in RCA: 95] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 02/26/2016] [Indexed: 12/12/2022]
Abstract
Type 1 (T1D) and type 2 (T2D) diabetes share pathophysiological characteristics, yet mechanistic links have remained elusive. T1D results from autoimmune destruction of pancreatic beta cells, whereas beta cell failure in T2D is delayed and progressive. Here we find a new genetic component of diabetes susceptibility in T1D non-obese diabetic (NOD) mice, identifying immune-independent beta cell fragility. Genetic variation in Xrcc4 and Glis3 alters the response of NOD beta cells to unfolded protein stress, enhancing the apoptotic and senescent fates. The same transcriptional relationships were observed in human islets, demonstrating the role of beta cell fragility in genetic predisposition to diabetes.
Collapse
Affiliation(s)
- James Dooley
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Lei Tian
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Susann Schonefeldt
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | | | - Josselyn E Garcia-Perez
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Emanuela Pasciuto
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Daniele Di Marino
- Department of Informatics, Università della Svizzera Italiana, Lugano, Switzerland
| | - Edward J Carr
- Lymphocyte Signaling and Development Institute Strategic Programme, Babraham Institute, Cambridge, UK
| | - Nikolay Oskolkov
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
| | - Valeriya Lyssenko
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden.,Department of Translational Pathophysiology, Steno Diabetes Center, Gentofte, Denmark
| | - Dean Franckaert
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Vasiliki Lagou
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium.,Department of Neurosciences, University of Leuven, Leuven, Belgium
| | - Lut Overbergh
- Department of Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium
| | - Jonathan Vandenbussche
- Department of Medical Protein Research, VIB, Ghent, Belgium.,Department of Biochemistry, Ghent University, Ghent, Belgium
| | | | - Genevieve Chabot-Roy
- Immunology-Oncology Section, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada
| | - Jane E Dahlstrom
- Australian National University Medical School, Canberra, Australian Capital Territory, Australia.,Department of Anatomical Pathology, Canberra Hospital, Garran, Australian Capital Territory, Australia
| | - D Ross Laybutt
- Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia
| | - Nikolai Petrovsky
- Department of Endocrinology, Flinders University, Adelaide, South Australia, Australia
| | - Luis Socha
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Kris Gevaert
- Department of Medical Protein Research, VIB, Ghent, Belgium.,Department of Biochemistry, Ghent University, Ghent, Belgium
| | - Anton M Jetten
- Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, US National Institutes of Health, Research Triangle Park, North Carolina, USA
| | - Diether Lambrechts
- Vesalius Research Center, VIB, Leuven, Belgium.,Department of Oncology, University of Leuven, Leuven, Belgium
| | - Michelle A Linterman
- Lymphocyte Signaling and Development Institute Strategic Programme, Babraham Institute, Cambridge, UK
| | - Chris C Goodnow
- Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia
| | - Christopher J Nolan
- Australian National University Medical School, Canberra, Australian Capital Territory, Australia.,Department of Endocrinology, Canberra Hospital, Garran, Australian Capital Territory, Australia
| | - Sylvie Lesage
- Immunology-Oncology Section, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.,Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada
| | - Susan M Schlenner
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| | - Adrian Liston
- Center for the Biology of Disease, VIB, Leuven, Belgium.,Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
| |
Collapse
|
8
|
Abstract
Type 1 diabetes (T1D) is a metabolic disease that results from the autoimmune attack against insulin-producing β-cells in the pancreatic islets of Langerhans. Currently, there is no treatment to restore endogenous insulin secretion in patients with autoimmune diabetes. In the last years, the development of new therapies to induce long-term tolerance has been an important medical health challenge. Apoptosis is a physiological mechanism that contributes to the maintenance of immune tolerance. Apoptotic cells are a source of autoantigens that induce tolerance after their removal by antigen presenting cells (APCs) through a process called efferocytosis. Efferocytosis will not cause maturation in dendritic cells, one of the most powerful APCs, and this process could induce tolerance rather than autoimmunity. However, failure of this mechanism due to an increase in the rate of β-cells apoptosis and/or defects in efferocytosis results in activation of APCs, contributing to inflammation and to the loss of tolerance to self. In fact, T1D and other autoimmune diseases are associated to enhanced apoptosis of target cells and defective apoptotic cell clearance. Although further research is needed, the clinical relevance of immunotherapies based on apoptosis could prove to be very important, as it has translational potential in situations that require the reestablishment of immunological tolerance, such as autoimmune diseases. This review summarizes the effects of apoptosis of β-cells towards autoimmunity or tolerance and its application in the field of emerging immunotherapies.
Collapse
|
9
|
Kaddis JS, Pugliese A, Atkinson MA. A run on the biobank: what have we learned about type 1 diabetes from the nPOD tissue repository? Curr Opin Endocrinol Diabetes Obes 2015; 22:290-5. [PMID: 26087339 DOI: 10.1097/med.0000000000000171] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
PURPOSE OF REVIEW Since the inaugural year of its biobank in 2007, the Network for Pancreatic Organ Donors with Diabetes program has provided 70 370 human samples to 127 investigators worldwide for projects focused on the pathogenesis of type 1 diabetes (T1D). The purpose of this review was to highlight major advances in our understanding of T1D using works that contain original data from experiments utilizing biospecimens provided by the Network for Pancreatic Organ Donors with Diabetes program. A total of 15 studies, published between 1 June 2013 and 31 December 2014, were selected using various search and filter strategies. RECENT FINDINGS The type and frequency of B and/or T-cell immune markers in both the endocrine and exocrine compartments vary in T1D. Enterovirus signals have been identified as having new proteins in the extracellular matrix around infiltrated islets. Novel genes within human islet cell types have been shown to play a role in immunity, infiltration, inflammation, disease progression, cell mass and function. Various cytokines and a complement degradation product have also been detected in the blood or surrounding pancreatic ducts/vasculature. SUMMARY These findings, from T1D donors across the disease spectrum, emphasize the notion that pathogenic heterogeneity is a hallmark of the disorder.
Collapse
Affiliation(s)
- John S Kaddis
- aDepartment of Information Sciences, City of Hope, Duarte, California bDiabetes Research Institute and Departments of Medicine, Microbiology and Immunology, University of Miami Miller School of Medicine, Miami cDepartments of Pathology and Pediatrics, University of Florida, Gainesville, Florida, USA
| | | | | |
Collapse
|
10
|
Stechova K, Kolar M, Blatny R, Halbhuber Z, Vcelakova J, Hubackova M, Petruzelkova L, Sumnik Z, Obermannova B, Pithova P, Stavikova V, Krivjanska M, Neuwirth A, Kolouskova S, Filipp D. Healthy first-degree relatives of patients with type 1 diabetes exhibit significant differences in basal gene expression pattern of immunocompetent cells compared to controls: expression pattern as predeterminant of autoimmune diabetes. Scand J Immunol 2015; 75:210-9. [PMID: 21923738 DOI: 10.1111/j.1365-3083.2011.02637.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Expression features of genetic landscape which predispose an individual to the type 1 diabetes are poorly understood. We addressed this question by comparing gene expression profile of freshly isolated peripheral blood mononuclear cells isolated from either patients with type 1 diabetes (T1D), or their first-degree relatives or healthy controls. Our aim was to establish whether a distinct type of 'prodiabetogenic' gene expression pattern in the group of relatives of patients with T1D could be identified. Whole-genome expression profile of nine patients with T1D, their ten first-degree relatives and ten healthy controls was analysed using the human high-density expression microarray chip. Functional aspects of candidate genes were assessed using the MetaCore software. The highest number of differentially expressed genes (547) was found between the autoantibody-negative healthy relatives and the healthy controls. Some of them represent genes critically involved in the regulation of innate immune responses such as TLR signalling and CCR3 signalling in eosinophiles, humoral immune reactions such as BCR pathway, costimulation and cytokine responses mediated by CD137, CD40 and CD28 signalling and IL-1 proinflammatory pathway. Our data demonstrate that expression profile of healthy relatives of patients with T1D is clearly distinct from the pattern found in the healthy controls. That especially concerns differential activation status of genes and signalling pathways involved in proinflammatory processes and those of innate immunity and humoral reactivity. Thus, we posit that the study of the healthy relative's gene expression pattern is instrumental for the identification of novel markers associated with the development of diabetes.
Collapse
Affiliation(s)
- K Stechova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - M Kolar
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - R Blatny
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - Z Halbhuber
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - J Vcelakova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - M Hubackova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - L Petruzelkova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - Z Sumnik
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - B Obermannova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - P Pithova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - V Stavikova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - M Krivjanska
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - A Neuwirth
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - S Kolouskova
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| | - D Filipp
- Department of Paediatrics, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicLaboratory of Genomics and Bioinformatics, Institute of Molecular Genetics AS CR, Prague, Czech RepublicCentral European Biosystems, Prague, Czech RepublicDepartment of Internal Medicine, 2nd Medical Faculty of Charles University and University Hospital Motol, Prague, Czech RepublicDepartment of Immunobiology, Institute of Molecular Genetics, Czech Academy of Science, Prague, Czech Republic
| |
Collapse
|
11
|
Askenasy N. Less Is More: The Detrimental Consequences of Immunosuppressive Therapy in the Treatment of Type-1 Diabetes. Int Rev Immunol 2015; 34:523-37. [DOI: 10.3109/08830185.2015.1010723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
12
|
The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice. PLoS One 2015; 10:e0120760. [PMID: 25789863 PMCID: PMC4366223 DOI: 10.1371/journal.pone.0120760] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 01/26/2015] [Indexed: 12/19/2022] Open
Abstract
Diabetes mellitus is a chronic metabolic disorder that significantly affects human health and well-being. The Solute carrier transporters (SLCs), particularly the Organic anion/cation transporters (Oats/Octs/Octns), Organic anion transporting polypeptides (Oatps) and Oligopeptide transporters (Pepts) are essential membrane proteins responsible for cellular uptake of many endogenous and exogenous substances such as clinically important drugs. They are widely expressed in mammalian key organs especially the kidney and liver, in which they facilitate the influx of various drug molecules, thereby determining their distribution and elimination in body. The altered expression of SLCs in diabetes mellitus could have a profound and clinically significant influence on drug therapies. In this study, we extensively investigated the renal and hepatic expression of twenty essential SLCs in the type 1 diabetic Ins2Akita murine model that develops both hyperglycemia and diabetes-related complications using real-time PCR and immunoblotting analysis. We found that the renal expression of mOatp1a1, mOatp1a6, mOat1, mOat3, mOat5, mOct2 and mPept2 was decreased; while that of mPept1 was increased at the mRNA level in the diabetic mice compared with non-diabetic controls. We found up-regulated mRNA expression of mOatp1a4, mOatp1c1, mOctn2, mOct3 and mPept1 as well as down-regulation of mOatp1a1 in the livers of diabetic mice. We confirmed the altered protein expression of several SLCs in diabetic mice, especially the decreased renal and hepatic expression of mOatp1a1. We also found down-regulated protein expression of mOat3 and mOctn1 in the kidneys as well as increased protein expression of mOatp1a4 and mOct3 in the livers of diabetic mice. Our findings contribute to better understanding the modulation of SLC transporters in type 1 diabetes mellitus, which is likely to affect the pharmacokinetic performance of drugs that are transported by these transporters and therefore, forms the basis of future therapeutic optimization of regimens in patients with type 1 diabetes mellitus.
Collapse
|
13
|
IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun 2015; 3:1. [PMID: 25627031 PMCID: PMC4308930 DOI: 10.1186/s40478-014-0179-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2014] [Accepted: 12/15/2014] [Indexed: 01/11/2023] Open
Abstract
Introduction Anti-acetylcholine receptor (AChR) autoantibodies target muscles in spontaneous human myasthenia gravis (MG) and its induced experimental autoimmune model MG (EAMG). The aim of this study was to identify novel functional mechanisms occurring in the muscle pathology of myasthenia. Results A transcriptome analysis performed on muscle tissue from MG patients (compared with healthy controls) and from EAMG rats (compared with control rats) revealed a deregulation of genes associated with the Interleukin-6 (IL-6) and Insulin-Like Growth Factor 1 (IGF-1) pathways in both humans and rats. The expression of IL-6 and its receptor IL-6R transcripts was found to be altered in muscles of EAMG rats and mice compared with control animals. In muscle biopsies from MG patients, IL-6 protein level was higher than in control muscles. Using cultures of human muscle cells, we evaluated the effects of anti-AChR antibodies on IL-6 production and on the phosphorylation of Protein Kinase B (PKB/Akt). Most MG sera and some monoclonal anti-AChR antibodies induced a significant increase in IL-6 production by human muscle cells. Furthermore, Akt phosphorylation in response to insulin was decreased in the presence of monoclonal anti-AChR antibodies. Conclusions Anti-AChR antibodies alter IL-6 production by muscle cells, suggesting a putative novel functional mechanism of action for the anti-AChR antibodies. IL-6 is a myokine with known effects on signaling pathways such as Akt/mTOR (mammalian Target of Rapamycin). Since Akt plays a key role in multiple cellular processes, the reduced phosphorylation of Akt by the anti-AChR antibodies may have a significant impact on the muscle fatigability observed in MG patients. Electronic supplementary material The online version of this article (doi:10.1186/s40478-014-0179-6) contains supplementary material, which is available to authorized users.
Collapse
|
14
|
Evangelista AF, Collares CVA, Xavier DJ, Macedo C, Manoel-Caetano FS, Rassi DM, Foss-Freitas MC, Foss MC, Sakamoto-Hojo ET, Nguyen C, Puthier D, Passos GA, Donadi EA. Integrative analysis of the transcriptome profiles observed in type 1, type 2 and gestational diabetes mellitus reveals the role of inflammation. BMC Med Genomics 2014; 7:28. [PMID: 24885568 PMCID: PMC4066312 DOI: 10.1186/1755-8794-7-28] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Accepted: 03/27/2014] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Type 1 diabetes (T1D) is an autoimmune disease, while type 2 (T2D) and gestational diabetes (GDM) are considered metabolic disturbances. In a previous study evaluating the transcript profiling of peripheral mononuclear blood cells obtained from T1D, T2D and GDM patients we showed that the gene profile of T1D patients was closer to GDM than to T2D. To understand the influence of demographical, clinical, laboratory, pathogenetic and treatment features on the diabetes transcript profiling, we performed an analysis integrating these features with the gene expression profiles of the annotated genes included in databases containing information regarding GWAS and immune cell expression signatures. METHODS Samples from 56 (19 T1D, 20 T2D, and 17 GDM) patients were hybridized to whole genome one-color Agilent 4x44k microarrays. Non-informative genes were filtered by partitioning, and differentially expressed genes were obtained by rank product analysis. Functional analyses were carried out using the DAVID database, and module maps were constructed using the Genomica tool. RESULTS The functional analyses were able to discriminate between T1D and GDM patients based on genes involved in inflammation. Module maps of differentially expressed genes revealed that modulated genes: i) exhibited transcription profiles typical of macrophage and dendritic cells; ii) had been previously associated with diabetic complications by association and by meta-analysis studies, and iii) were influenced by disease duration, obesity, number of gestations, glucose serum levels and the use of medications, such as metformin. CONCLUSION This is the first module map study to show the influence of epidemiological, clinical, laboratory, immunopathogenic and treatment features on the transcription profiles of T1D, T2D and GDM patients.
Collapse
Affiliation(s)
- Adriane F Evangelista
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Cristhianna VA Collares
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
- Division Clinical Immunology, Faculty of Medicine of Ribeirão Preto, (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Danilo J Xavier
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Claudia Macedo
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Fernanda S Manoel-Caetano
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Diane M Rassi
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Maria C Foss-Freitas
- Division Clinical Immunology, Faculty of Medicine of Ribeirão Preto, (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Milton C Foss
- Division Clinical Immunology, Faculty of Medicine of Ribeirão Preto, (USP), 14049-900 Ribeirão Preto, SP, Brazil
| | - Elza T Sakamoto-Hojo
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
- Department of Biology, Faculty of Philosophy, Sciences and Letters, (USP), 14040-900 Ribeirão Preto, SP, Brazil
| | - Catherine Nguyen
- INSERM U1090, TAGC, Aix-Marseille Université IFR137, 13100 Marseille, France
| | - Denis Puthier
- INSERM U1090, TAGC, Aix-Marseille Université IFR137, 13100 Marseille, France
| | - Geraldo A Passos
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
- Disciplines of Genetics and Molecular Biology, Department of Morphology, Physiology and Basic Pathology, School of Dentistry of Ribeirão Preto, USP, 14040-904 Ribeirão Preto, SP, Brazil
| | - Eduardo A Donadi
- Molecular Immunogenetics Group, Department of Genetics, Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP), 14049-900 Ribeirão Preto, SP, Brazil
- Division Clinical Immunology, Faculty of Medicine of Ribeirão Preto, (USP), 14049-900 Ribeirão Preto, SP, Brazil
| |
Collapse
|
15
|
Abstract
PURPOSE OF REVIEW β Cells represent one of many cell types in heterogeneous pancreatic islets and play the central role in maintaining glucose homeostasis, such that disrupting β-cell function leads to diabetes. This review summarizes the methods for isolating and characterizing β cells, and describes integrated 'omics' approaches used to define the β cell by its transcriptome and proteome. RECENT FINDINGS RNA sequencing and mass spectrometry-based protein identification have now identified RNA and protein profiles for mouse and human pancreatic islets and β cells, and for β-cell lines. Recent publications have outlined these profiles and, more importantly, have begun to assign the presence or absence of specific genes and regulatory molecules to β-cell function and dysfunction. Overall, researchers have focused on understanding the pathophysiology of diabetes by connecting genome, transcriptome, proteome, and regulatory RNA profiles with findings from genome-wide association studies. SUMMARY Studies employing these relatively new techniques promise to identify specific genes or regulatory RNAs with altered expression as β-cell function begins to deteriorate in the spiral toward the development of diabetes. The ultimate goal is to identify the potential therapeutic targets to prevent β-cell dysfunction and thereby better treat the individual with diabetes. VIDEO ABSTRACT http://links.lww.com/COE/A5.
Collapse
Affiliation(s)
- David M Blodgett
- Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | | | | |
Collapse
|
16
|
Collares CVA, Evangelista AF, Xavier DJ, Takahashi P, Almeida R, Macedo C, Manoel-Caetano F, Foss MC, Foss-Freitas MC, Rassi DM, Sakamoto-Hojo ET, Passos GA, Donadi EA. Transcriptome meta-analysis of peripheral lymphomononuclear cells indicates that gestational diabetes is closer to type 1 diabetes than to type 2 diabetes mellitus. Mol Biol Rep 2013; 40:5351-8. [DOI: 10.1007/s11033-013-2635-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Accepted: 04/30/2013] [Indexed: 01/10/2023]
|
17
|
Vcelakova J, Blatny R, Halbhuber Z, Kolar M, Neuwirth A, Petruzelkova L, Ulmannova T, Kolouskova S, Sumnik Z, Pithova P, Krivjanska M, Filipp D, Stechova K. The effect of diabetes-associated autoantigens on cell processes in human PBMCs and their relevance to autoimmune diabetes development. J Diabetes Res 2013; 2013:589451. [PMID: 23841104 PMCID: PMC3694381 DOI: 10.1155/2013/589451] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Accepted: 05/20/2013] [Indexed: 12/18/2022] Open
Abstract
Type 1 Diabetes (T1D) is considered to be a T-helper- (Th-) 1 autoimmune disease; however, T1D pathogenesis likely involves many factors, and sufficient tools for autoreactive T cell detection for the study of this disease are currently lacking. In this study, using gene expression microarrays, we analysed the effect of diabetes-associated autoantigens on peripheral blood mononuclear cells (PBMCs) with the purpose of identifying (pre)diabetes-associated cell processes. Twelve patients with recent onset T1D, 18 first-degree relatives of the TD1 patients (DRL; 9/18 autoantibody positive), and 13 healthy controls (DV) were tested. PBMCs from these individuals were stimulated with a cocktail of diabetes-associated autoantigens (proinsulin, IA-2, and GAD65-derived peptides). After 72 hours, gene expression was evaluated by high-density gene microarray. The greatest number of functional differences was observed between relatives and controls (69 pathways), from which 15% of the pathways belonged to "immune response-related" processes. In the T1D versus controls comparison, more pathways (24%) were classified as "immune response-related." Important pathways that were identified using data from the T1D versus controls comparison were pathways involving antigen presentation by MHCII, the activation of Th17 and Th22 responses, and cytoskeleton rearrangement-related processes. Genes involved in Th17 and TGF-beta cascades may represent novel, promising (pre)diabetes biomarkers.
Collapse
Affiliation(s)
- Jana Vcelakova
- Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, V Uvalu 84, 15006 Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
La Torre D. Immunobiology of beta-cell destruction. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013; 771:194-218. [PMID: 23393680 DOI: 10.1007/978-1-4614-5441-0_16] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Type 1 diabetes is a chronic disease characterized by severe insulin deficiency and hyperglycemia, due to autoimmune destruction of pancreatic islets of Langerhans. A susceptible genetic background is necessary, but not sufficient, for the development of the disease. Epidemiological and clinical observations underscore the importance of environmental factors as triggers of type 1 diabetes, currently under investigation. Islet-specific autoantibodies precede clinical onset by months to years and are established tools for risk prediction, yet minor players in the pathogenesis of the disease. Many efforts have been made to elucidate disease-relevant defects in the key immune effectors of islet destruction, from the early failure of specific tolerance to the vicious circle of destructive insulitis. However, the events triggering islet autoimmunity as well as the transition to overt diabetes are still largely unknown, making prevention and treatment strategies still a challenge.
Collapse
Affiliation(s)
- Daria La Torre
- Lund University, Clinical Research Center (CRC), Department of Clinical Sciences, Malmö, Sweden.
| |
Collapse
|
19
|
Abstract
Biomarkers are useful tools for research into type 1 diabetes (T1D) for a number of purposes, including elucidation of disease pathogenesis, risk prediction, and therapeutic monitoring. Susceptibility genes and islet autoantibodies are currently the most useful biomarkers for T1D risk prediction. However, these markers do not fully meet the needs of scientists and physicians for several reasons. First, improvement of the specificity and sensitivity is still desirable to achieve better positive predictive values. Second, autoantibodies appear relatively late in the disease process, thus limiting their value in early disease prediction. Third, the currently available biomarkers are not useful for assessing therapeutic outcomes because some are not involved in the disease process (autoantibodies) and others do not change during disease progression (susceptibility genes). Therefore, considerable effort has been devoted to the discovery of novel T1D biomarkers in the last three decades. The advent of high-throughput technologies for genetic, transcriptomic, and proteomic studies has allowed genome-wide examinations of genetic polymorphisms, global gene changes, and protein expression changes in T1D patients and prediabetic subjects. These large-scale studies resulted in the discovery of a large number of susceptibility genes and changes in gene and protein expression. While these studies have provided a number of novel biomarker candidates, their clinical benefits remain to be evaluated in prospective studies, and no new "star biomarker" has been identified until now. Previous studies suggest that significant improvements in study design and analytical methodologies have to be made to identify clinically relevant biomarkers. In this review, we discuss progress, opportunities, challenges, and future directions in the development of T1D biomarkers, mainly by focusing on the genetic, transcriptomic, and proteomic aspects.
Collapse
Affiliation(s)
- Yulan Jin
- Center for Biotechnology and Genomic Medicine and Department of Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA
| | | |
Collapse
|
20
|
Énée É, Kratzer R, Arnoux JB, Barilleau E, Hamel Y, Marchi C, Beltrand J, Michaud B, Chatenoud L, Robert JJ, van Endert P. ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes 2012; 61:1779-84. [PMID: 22586580 PMCID: PMC3379659 DOI: 10.2337/db12-0071] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Type 1 diabetes results from the destruction of β-cells by an autoimmune T-cell response assisted by antigen-presenting B cells producing autoantibodies. CD8(+) T-cell responses against islet cell antigens, thought to play a central role in diabetes pathogenesis, can be monitored using enzyme-linked immunosorbent spot (ELISpot) assays. However, such assays have been applied to monitoring of adult patients only, leaving aside the large and increasing pediatric patient population. The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes.
Collapse
Affiliation(s)
- Émmanuelle Énée
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Roland Kratzer
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Jean-Baptiste Arnoux
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
- Hôpital Necker, Service d’endocrinologie, Unité fonctionnelle diabétologie, Paris, France
| | - Emilie Barilleau
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Yamina Hamel
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Christophe Marchi
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Jacques Beltrand
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
- Hôpital Necker, Service d’endocrinologie, Unité fonctionnelle diabétologie, Paris, France
| | - Bénédicte Michaud
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Lucienne Chatenoud
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
| | - Jean-Jacques Robert
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
- Hôpital Necker, Service d’endocrinologie, Unité fonctionnelle diabétologie, Paris, France
| | - Peter van Endert
- INSERM, Unité 1013, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, Paris, France
- Corresponding author: Peter van Endert,
| |
Collapse
|
21
|
Yuan Y, Zhang J, Liang G, Yang X. Rapid fluorescent detection of neurogenin3 by CdTe quantum dot aggregation. Analyst 2012; 137:1775-8. [PMID: 22407238 DOI: 10.1039/c2an16166d] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Here we report a facile immunoassay for detecting a synthetic peptide fragment of neurogenin3 (amino acid sequence: SKQRRSRRKKANDRERNRMH) by harnessing the aggregation-dependent fluorescence property of antibody-conjugated CdTe quantum dots in the presence of the target.
Collapse
Affiliation(s)
- Yue Yuan
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China
| | | | | | | |
Collapse
|
22
|
Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, Eberlein J, Hildemann SK, Homann D. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 2012; 61:436-46. [PMID: 22210319 PMCID: PMC3266427 DOI: 10.2337/db11-0853] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
More than one-half of the ~50 human chemokines have been associated with or implicated in the pathogenesis of type 1 diabetes, yet their actual expression patterns in the islet environment of type 1 diabetic patients remain, at present, poorly defined. Here, we have integrated a human islet culture system, murine models of virus-induced and spontaneous type 1 diabetes, and the histopathological examination of pancreata from diabetic organ donors with the goal of providing a foundation for the informed selection of potential therapeutic targets within the chemokine/receptor family. Chemokine (C-C motif) ligand (CCL) 5 (CCL5), CCL8, CCL22, chemokine (C-X-C motif) ligand (CXCL) 9 (CXCL9), CXCL10, and chemokine (C-X3-C motif) ligand (CX3CL) 1 (CX3CL1) were the major chemokines transcribed (in an inducible nitric oxide synthase-dependent but not nuclear factor-κB-dependent fashion) and translated by human islet cells in response to in vitro inflammatory stimuli. CXCL10 was identified as the dominant chemokine expressed in vivo in the islet environment of prediabetic animals and type 1 diabetic patients, whereas CCL5, CCL8, CXCL9, and CX3CL1 proteins were present at lower levels in the islets of both species. Of importance, additional expression of the same chemokines in human acinar tissues emphasizes an underappreciated involvement of the exocrine pancreas in the natural course of type 1 diabetes that will require consideration for additional type 1 diabetes pathogenesis and immune intervention studies.
Collapse
Affiliation(s)
- Suparna A. Sarkar
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
| | - Catherine E. Lee
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
| | - Francisco Victorino
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
- Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado
| | - Tom T. Nguyen
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
| | - Jay A. Walters
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
| | - Adam Burrack
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
- Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado
| | - Jens Eberlein
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
| | | | - Dirk Homann
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
- Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado
- Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado
- Corresponding author: Dirk Homann,
| |
Collapse
|
23
|
Han D, Leyva CA, Matheson D, Mineo D, Messinger S, Blomberg BB, Hernandez A, Meneghini LF, Allende G, Skyler JS, Alejandro R, Pugliese A, Kenyon NS. Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clin Immunol 2011; 139:290-301. [PMID: 21414848 PMCID: PMC3096683 DOI: 10.1016/j.clim.2011.02.016] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Revised: 02/14/2011] [Accepted: 02/17/2011] [Indexed: 12/17/2022]
Abstract
There is a need for biomarkers to monitor the development and progression of type 1 DM. We analyzed mRNA expression levels for granzyme B, perforin, fas ligand, TNF-α, IFN-γ, Foxp3, IL-10, TGF-β, IL-4, IL-6, IL-17, Activation-induced cytidine deaminase (AID) and Immunoglobulin G gamma chain (IgG<gamma>) genes in peripheral blood of at-risk, new-onset and long-term type 1 DM , and healthy controls. The majority of the genes were suppressed in long-term type 1 DM compared to controls and new-onset patients. IFN-γ, IL-4 and IL-10 mRNA levels were significantly higher in new-onset compared to at-risk and long-term groups. There was decreased mRNA expression for AID and IgG<gamma> and up-regulation of IFN-γ with age in controls. Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease.
Collapse
Affiliation(s)
- Dongmei Han
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, FL 33136, USA.
| | - Carlos A. Leyva
- Division of Pediatric Endocrinology, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Della Matheson
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Division of Diabetes, Endocrinology, and Metabolism, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Davide Mineo
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Shari Messinger
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Epidemiology & Public Health, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Bonnie B. Blomberg
- Department of Microbiology and Immunology, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Ana Hernandez
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Luigi F. Meneghini
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Division of Diabetes, Endocrinology, and Metabolism, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Gloria Allende
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Jay S. Skyler
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Division of Diabetes, Endocrinology, and Metabolism, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Medicine, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Rodolfo Alejandro
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Medicine, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Alberto Pugliese
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Microbiology and Immunology, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Division of Diabetes, Endocrinology, and Metabolism, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Medicine, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| | - Norma S. Kenyon
- Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Medicine, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA,Department of Surgery, Leonard Miller School of Medicine, University of Miami, Miami, FL 33136, USA
| |
Collapse
|
24
|
Abstract
BACKGROUND Type 1 diabetes, a multifactorial disease with a strong genetic component, is caused by the autoimmune destruction of pancreatic β cells. The major susceptibility locus maps to the HLA class II genes at 6p21, although more than 40 non-HLA susceptibility gene markers have been confirmed. CONTENT Although HLA class II alleles account for up to 30%-50% of genetic type 1 diabetes risk, multiple non-MHC loci contribute to disease risk with smaller effects. These include the insulin, PTPN22, CTLA4, IL2RA, IFIH1, and other recently discovered loci. Genomewide association studies performed with high-density single-nucleotide-polymorphism genotyping platforms have provided evidence for a number of novel loci, although fine mapping and characterization of these new regions remain to be performed. Children born with the high-risk genotype HLADR3/4-DQ8 comprise almost 50% of children who develop antiislet autoimmunity by the age of 5 years. Genetic risk for type 1 diabetes can be further stratified by selection of children with susceptible genotypes at other diabetes genes, by selection of children with a multiple family history of diabetes, and/or by selection of relatives that are HLA identical to the proband. SUMMARY Children with the HLA-risk genotypes DR3/4-DQ8 or DR4/DR4 who have a family history of type 1 diabetes have more than a 1 in 5 risk for developing islet autoantibodies during childhood, and children with the same HLA-risk genotype but no family history have approximately a 1 in 20 risk. Determining extreme genetic risk is a prerequisite for the implementation of primary prevention trials, which are now underway for relatives of individuals with type 1 diabetes.
Collapse
Affiliation(s)
- Andrea K Steck
- Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045-6511, USA.
| | | |
Collapse
|